Sign In
Buy PFE
$25.69
+0.335 (+1.32%)
At Close: Jun 04, 2026
Pfizer Abandons Its Leading Weight Loss Candidate. Should You Sell the Stock?
08:15am, Friday, 18'th Apr 2025
Although it isn't the largest therapeutic area in the pharmaceutical industry, the market for weight loss therapies has caught fire in recent years. The leading medicines in this field include househo
3 Magnificent S&P 500 Dividend Stocks Down 11% to 63% to Buy and Hold Forever
03:05am, Friday, 18'th Apr 2025
The past few weeks have been tough for the market. Tariffs are obviously a direct threat to most companies' top and bottom lines, while the broad economic weakness they might cause is nearly impossibl
Pfizer (PFE) Laps the Stock Market: Here's Why
06:50pm, Thursday, 17'th Apr 2025
Pfizer (PFE) closed the most recent trading day at $22.15, moving +0.48% from the previous trading session.
GSK & PFE's RSV Vaccines Recommended for Use in Adults Aged 50-59
10:20am, Thursday, 17'th Apr 2025
The U.S. CDC's Advisory Committee recommends the use of GSK and Pfizer's RSV vaccines in adults aged 50-59 who are at high risk of severe RSV disease.
Trump Tariff Plunge: 3 Phenomenal Stocks to Buy at Bargain Prices Right Now
03:51am, Thursday, 17'th Apr 2025
Just because Wall Street has proved to be a superior wealth creator over the long run doesn't mean stocks are impervious to bouts of volatility. Since President Donald Trump announced his "Liberation
Pfizer: Risks Priced In, Buy The Exceptional Valuation And Yield
12:58am, Thursday, 17'th Apr 2025
Pfizer has faced headwinds post-COVID, but remains a key player with a robust R&D pipeline and an attractive 7.5%+ dividend yield. The pharmaceutical industry thrives on high R&D investment and patent
ACIP Votes to Expand Recommendation for Pfizer's RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease
04:15pm, Wednesday, 16'th Apr 2025
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted to expand
Pfizer: Tasty 7% Yield
03:28pm, Wednesday, 16'th Apr 2025
Pfizer Inc.'s stock is trading at $22 with an 8% dividend yield, driven by market fears over losing vaccine revenues. The biopharma has a robust pipeline with potential mega blockbuster cancer drugs a
Why Pfizer Stock Topped the Market on Tuesday
06:53pm, Tuesday, 15'th Apr 2025
On Tuesday, investors continued to snap up shares of big pharmaceutical company Pfizer (PFE 1.51%). Somewhat counterintuitively, this week's rise came after the company announced it was ending the dev
Trump signs healthcare executive order that includes a win for pharma companies
05:43pm, Tuesday, 15'th Apr 2025
U.S. President Donald Trump directed his health department on Tuesday to work with Congress on revamping a law that allows Medicare to negotiate prescription drug prices, seeking to introduce a change
Will Pfizer approach Viking Therapeutics with a buyout proposal?
03:26pm, Tuesday, 15'th Apr 2025
Investors are running into Viking Therapeutics (NASDAQ: VKTX) this week after an incident of drug-induced liver injury pushed Pfizer (NYSE: PFE) into terminating the development of its weight-loss pil
Viking Therapeutics' VK2735 Candidate Likely Boosted By Pfizer's Woes
02:37pm, Tuesday, 15'th Apr 2025
13-week data from the Viking Therapeutics, Inc. phase 2 VENTURE-Oral Dosing trial using oral VK2735 for the treatment of patients with obesity, expected 2nd half of 2025. Pfizer's recent setbacks in w
European pharma companies issue demands to stay in EU ahead of expected US tariffs
02:33pm, Tuesday, 15'th Apr 2025
Nearly three dozen global pharmaceutical companies, in a letter to the head of the European Commission, demanded help to maintain operations in the EU despite threatened U.S. tariffs on imports, inclu
Pfizer Halts Obesity Pill Development Amid Safety Concerns
02:00pm, Tuesday, 15'th Apr 2025
PFE's decision to scrap the development of danuglipron comes after a study participant develops potential drug-induced liver injury.
Tariffs on generic drugs will cause companies to stop making them: Former FDA Commissioner Gottlieb
10:29am, Tuesday, 15'th Apr 2025
Dr. Scott Gottlieb, former FDA Commissioner, joins 'Squawk Box' to discuss current pharmaceutical imports under investigation, moving production for branded and generic drugs elsewhere, and much more.
